Review





Similar Products

blarcamesine hydrochloride  (MedChemExpress)
93
MedChemExpress blarcamesine hydrochloride
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Blarcamesine Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blarcamesine hydrochloride/product/MedChemExpress
Average 93 stars, based on 1 article reviews
blarcamesine hydrochloride - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
pkam bfp puro  (Addgene inc)
92
Addgene inc pkam bfp puro
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Pkam Bfp Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkam bfp puro/product/Addgene inc
Average 92 stars, based on 1 article reviews
pkam bfp puro - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
sig 1r agonist blarcamesine hydrochloride bla  (MedChemExpress)
93
MedChemExpress sig 1r agonist blarcamesine hydrochloride bla
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Sig 1r Agonist Blarcamesine Hydrochloride Bla, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sig 1r agonist blarcamesine hydrochloride bla/product/MedChemExpress
Average 93 stars, based on 1 article reviews
sig 1r agonist blarcamesine hydrochloride bla - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
resource source identifier recombinant dna pkam bfp puro unpublished archibald perkins addgene plasmid  (Addgene inc)
92
Addgene inc resource source identifier recombinant dna pkam bfp puro unpublished archibald perkins addgene plasmid
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Resource Source Identifier Recombinant Dna Pkam Bfp Puro Unpublished Archibald Perkins Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/resource source identifier recombinant dna pkam bfp puro unpublished archibald perkins addgene plasmid/product/Addgene inc
Average 92 stars, based on 1 article reviews
resource source identifier recombinant dna pkam bfp puro unpublished archibald perkins addgene plasmid - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
sig 1r agonist blarcamesine hydrochloride avex 73  (MedChemExpress)
93
MedChemExpress sig 1r agonist blarcamesine hydrochloride avex 73
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Sig 1r Agonist Blarcamesine Hydrochloride Avex 73, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sig 1r agonist blarcamesine hydrochloride avex 73/product/MedChemExpress
Average 93 stars, based on 1 article reviews
sig 1r agonist blarcamesine hydrochloride avex 73 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
blarcamesine  (MedChemExpress)
93
MedChemExpress blarcamesine
RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with <t>blarcamesine.</t> (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].
Blarcamesine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blarcamesine/product/MedChemExpress
Average 93 stars, based on 1 article reviews
blarcamesine - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with blarcamesine. (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].

Journal: Biomaterials Research

Article Title: Manufacturing Uniform Cerebral Organoids for Neurological Disease Modeling and Drug Evaluation

doi: 10.34133/bmr.0104

Figure Lengend Snippet: RTT-UCOs exhibited reduced neurite outgrowth of early neurons, which was recovered by treatment with blarcamesine. (A) Live images showing FOXG1-mCherry expression in WT- and RTT-UCOs at the indicated time points. (B) Bar graph of relative FOXG1 mRNA expression in the WT- and RTT-UCOs at days 15 and 30. (C) Immunofluorescence images showing MeCP2 expression in 2D neurons derived from WT- and RTT-UCOs at day 30 and neurite morphology marked with anti-TUBB3 antibody staining. Anti-doublecortin (DCX) antibodies were used to label newly generated neurons. (D and E) Bar graphs of the percentage of MeCP2-positive cell populations (D) and the neurite lengths (E) of 2D neurons derived from WT- and RTT-UCOs. (F) Schematic diagrams illustrating the overall neurite outgrowth assessment process via the live imaging of EGFP-expressed UCOs. (G) Live images showing real-time neurite outgrowth in WT- and RTT-UCOs over 4 d. (H) Neurite outgrowth curves showing gradually increasing lengths of outgrown neurites from 3D organoids. (I to K) Immunofluorescence images at day 4 and neurite outgrowth curves in the indicated conditions (NT, nontreated; Noc, nocodazole; Trof, trofinetide; Blar, blarcamesine). Significance of each group was calculated by comparing with the RTT group at indicated time point. Quantitative data from the fluorescence images are expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001. Scale bars, 1 mm (A and G), 50 μm (C), and 100 μm [magnified images in (G) and (I) to (K)].

Article Snippet: The following drugs were used for the treatment: 0.1 μM nocodazole (M1404, Sigma), 0.03 to 3 μM trofinetide (HY-16757, MedChemExpress), 0.03 to 3 μM blarcamesine hydrochloride (HY-101864, MedChemExpress), and 25 ng/ml BDNF.

Techniques: Expressing, Immunofluorescence, Derivative Assay, Staining, Generated, Imaging, Fluorescence